Cronos Group Inc.
TSX:CRON.TODrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $1.67B
- Beta
- 1.25
- P/E (TTM)
- -488.1
- EPS (TTM)
- -$0.01
Volume 0.15M
Average 0.19M
CRON.TO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cronos Group Inc.TSX: CRON.TO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $801.21K a year earlier. Trailing-twelve-month research & development was $3.68M. Over 3 fiscal years it compounded at -30.1% a year.
Context
- Research & development amounted to 3.0% of revenue in FY2025, down 0.6 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $919.26K.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 4.53M USD
- Year-over-year change
- +7.1%
- 4-year CAGR
- -32.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.53M | +7.1% |
| FY2024 | 2024-12-31 | 4.22M | -27.5% |
| FY2023 | 2023-12-31 | 5.83M | -56.0% |
| FY2022 | 2022-12-31 | 13.25M | -38.8% |
| FY2021 | 2021-12-31 | 21.66M | — |
Research & Development vs competitors
How CRON.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -8.7% is the 2nd highest of 4, against a peer median of -61.8%.
- Research & development amounts to 2.3% of revenue for CRON.TO, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$33.61M CAD | +45.4% | +25.2% | 6.6% | |
| LTM Mar 2026 | $3.68M USD | -8.7% | -30.1% | 2.3% | |
| LTM Feb 2026 | $246.09K USD | -61.8% | -42.8% | 0.0% | |
| LTM Jun 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Sep 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| Peer median (excluding CRON.TO) | — | -61.8% | -8.8% | 0.0% | |
Competitors are the stored peer set for CRON.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 64.02M | 87.54M | 87.03M | 117.5M | 149.15M |
| Cost of Revenue | 81.47M | 71.96M | 75.15M | 87.05M | 87.45M |
| Gross Profit | (17.45M) | 15.58M | 11.88M | 30.45M | 61.7M |
| Gross Margin | -27.3% | 17.8% | 13.7% | 25.9% | 41.4% |
| Research & Development | 21.66M | 13.25M | 5.83M | 4.22M | 4.53M |
| Selling, General & Admin | 120.67M | 101.64M | 80.74M | 76.74M | 75.01M |
| Operating Expenses | 272.09M | 128.01M | 96.48M | 106.91M | 79.54M |
| Depreciation & Amortization | 13.36M | 11.52M | 7.44M | 8.84M | 14.48M |
| EBITDA | (150.79M) | (93.81M) | (72.28M) | (45.37M) | (2.94M) |
| EBITDA Margin | -235.5% | -107.2% | -83.0% | -38.6% | -2.0% |
| Operating Income | (289.54M) | (112.44M) | (84.6M) | (76.46M) | (17.84M) |
| Operating Margin | -452.2% | -128.4% | -97.2% | -65.1% | -12.0% |
| Interest Income | 8.92M | 21.84M | 52.07M | 49.52M | 40.66M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 162.1M | (9.66M) | 11.1M | 113.01M | 419.21K |
| Income Before Tax | (127.44M) | (122.1M) | (73.49M) | 36.55M | (17.42M) |
| Pre-Tax Margin | -199.1% | -139.5% | -84.4% | 31.1% | -11.7% |
| Income Tax Expense | (427.41K) | 34.48M | (3.23M) | (3.44M) | (14.44M) |
| Net Income | (392.81M) | (170.26M) | (73.79M) | 41.04M | (9.61M) |
| Net Margin | -613.5% | -194.5% | -84.8% | 34.9% | -6.4% |
| EPS (Basic) | (0.34) | (0.42) | (0.18) | 0.10 | (0.03) |
| EPS (Diluted) | (0.34) | (0.42) | (0.18) | 0.10 | (0.03) |
| Weighted Avg Shares | 369.73M | 370.39M | 380.96M | 382.16M | 383.47M |
| Weighted Avg Shares (Diluted) | 370.39M | 370.39M | 380.96M | 382.16M | 383.47M |
Cronos Group Inc.
TSX:CRON.TO
Intrinsic Alpha fair value
Locked
Current Price
$4.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.